Neurocrine Biosciences, the San Diego-based biotech company, said today it raised about $10 million through a stock offering to Venrock Associates. The company (NASDAQ: [[ticker:NBIX]]) said it sold 4.78 million shares of Neurocrine at $2.09 apiece to Venrock. That’s about an 8 percent discount to the market price of $2.27 at yesterday’s close.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
